P.A.W. Capital Corp Buys Shares of 50,000 OptimizeRx Corp. $OPRX

P.A.W. Capital Corp purchased a new position in shares of OptimizeRx Corp. (NASDAQ:OPRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 50,000 shares of the company’s stock, valued at approximately $675,000. OptimizeRx comprises 1.3% of P.A.W. Capital Corp’s investment portfolio, making the stock its 18th biggest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OPRX. Parkman Healthcare Partners LLC acquired a new stake in shares of OptimizeRx during the first quarter worth $4,114,000. Invesco Ltd. acquired a new position in OptimizeRx in the first quarter valued at $2,542,000. Whetstone Capital Advisors LLC boosted its position in OptimizeRx by 11.7% during the first quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock valued at $13,062,000 after acquiring an additional 157,880 shares during the last quarter. Trexquant Investment LP bought a new stake in OptimizeRx during the first quarter valued at $470,000. Finally, Nuveen LLC acquired a new stake in OptimizeRx during the 1st quarter worth about $455,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

Insider Buying and Selling

In other news, CEO Stephen L. Silvestro sold 1,620 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $18.75, for a total transaction of $30,375.00. Following the transaction, the chief executive officer directly owned 188,916 shares of the company’s stock, valued at $3,542,175. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Patrick D. Spangler sold 11,120 shares of the stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $17.49, for a total value of $194,488.80. Following the completion of the transaction, the director owned 44,215 shares in the company, valued at approximately $773,320.35. This represents a 20.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Roth Capital reissued a “buy” rating on shares of OptimizeRx in a research note on Friday, August 8th. Citizens Jmp raised their target price on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a research note on Friday, November 7th. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. UBS Group set a $23.00 price target on OptimizeRx in a research note on Friday, October 10th. Finally, Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $16.88.

OptimizeRx Price Performance

OPRX stock opened at $14.12 on Wednesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The company’s 50-day moving average is $18.51 and its 200-day moving average is $15.51. The stock has a market capitalization of $263.21 million, a PE ratio of -26.15 and a beta of 1.24. OptimizeRx Corp. has a 1 year low of $3.99 and a 1 year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The business had revenue of $26.07 million for the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx had a positive return on equity of 4.50% and a negative net margin of 9.42%. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.